Growth Factor Receptor driven Proliferation Profiling Service
Creative Biolabs delivers a "biochemical fingerprint" of compound interactions with mitogenic machinery, quantifying receptor activation, kinase phosphorylation, and cell cycle progression. Our platform identifies the "proliferation paradox"—where high growth factor receptors (GFR) activation induces replication stress—by monitoring stalled replication complexes and PCNA phosphorylation. This provides mechanistic proof of genomic instability, enabling precise go/no-go decisions and robust regulatory filings for lead optimization and long-term safety assessments.
Background What We Can Offer Workflow Publication Why Choose Us FAQs Customer Review Related Services Contact Us
The Biological Mandate: Why GFR Profiling Matters
GFRs drive oncogenesis through ligand-independent activation (e.g., EGFRvIII, L858R) and pathological overexpression. Creative Biolabs analyzes the EGFR proliferation paradox, where excessive signaling induces replication stress by stalling complexes via PCNA phosphorylation, creating a detectable window for early carcinogenicity. We map (epi)genetic dysregulation, such as MYC promoter hypomethylation, and the hijacking of insulin/IGF-1R hybrid receptors that bypass standard controls. By quantifying the EGFR/KRAS/MYC axis synergy, we reveal how GFR activation stabilizes MYC to drive metabolic reprogramming and replicative immortality, providing high-fidelity data for therapeutic and safety assessments.
Comprehensive GFR Profiling Capabilities
Creative Biolabs offers an expansive suite of analytical services tailored to the specific behavior of various receptor families. Our platform is designed to detect not only canonical signaling but also the aberrant interactions that drive carcinogenesis.
ErbB Family (HER1-4) Profiling
Our ErbB platform provides high-resolution dimerization fingerprinting for all 28 receptor combinations. We specialize in detecting ligand-independent activation from mutations like EGFR L858R or EGFRvIII. Additionally, we quantify HER2/HER3 recruitment, a key driver of signal amplification and therapeutic resistance.
Fibroblast Growth Factor Receptor (FGFR1-4) Analysis
We detect molecular "isoform switching" between FGFR IIIb and IIIc, a hallmark of EMT. Our service characterizes FGFR fusion proteins and chromosomal rearrangements, assessing their mitogenic impact. By tracking PLCγ and FRS2 activation, we map how receptors bypass standard controls.
Insulin & IGF-1 Receptor Axis
We map metabolic-mitogenic cross-talk by quantifying IR/IGF-1R hybrid receptors, which exhibit high mitogenic potency. Our platform distinguishes between IR-A and IR-B isoforms, providing critical data for drug safety. We also measure IRS-1/2 phosphorylation flux to identify hijacked metabolic pathways.
Downstream "Mitogenic Engine" Diagnostics
Our diagnostics quantify the EGFR/KRAS/MYC axis to determine how signals stabilize the MYC oncoprotein. We monitor CDK4/6 and Cyclin D1 flux to define cell cycle kinetics. Additionally, PCNA phosphorylation and MCM10 levels are measured to identify stalled replication phenotypes.
Explore Our Full Capability List - Inquire for a Detailed Service Catalog
Workflow
Creative Biolabs utilizes a structured, multi-parametric workflow designed to transition seamlessly from receptor engagement to phenotypic outcome.
Publication
Fibroblast growth factor receptor (FGFR) signaling plays essential roles in skin physiology, including melanocyte regulation and wound healing. In melanoma, this pathway is often suppressed due to constitutive activation of the MAPK pathway driven by BRAF/NRAS mutations. However, during targeted therapy with BRAF/MEK inhibitors, FGF/FGFR signaling can be reactivated, contributing to drug resistance, angiogenesis, and tumor survival. This review summarizes current knowledge on FGFR signaling in skin cancers and explores its potential as a therapeutic target, including in ongoing clinical trials such as LOGIC-2.
Fig.1 Mechanism of FGF1-mediated BRAF inhibitor resistance in melanoma. 1
Why Choose Us?
Creative Biolabs stands at the forefront of signal transduction research, offering a level of predictive accuracy that standard high-throughput screening platforms cannot match. Our unique advantage lies in our multi-tiered approach that bridges the gap between metabolic signaling and mitogenic flux. Our protocols are grounded in published data demonstrating a high correlation between our in vitro GFR signatures and in vivo oncogenic transformation. By integrating epigenetic profiling—such as methylation mapping of the MYC promoter—we provide a definitive assessment of whether a compound induces global metabolic reprogramming typical of aggressive carcinomas.
Experience the Creative Biolabs Advantage - Get a Custom Quote Today
FAQs
Can you perform this profiling on primary human cells?
Yes. While we have a vast library of cell lines, we frequently perform these assays on primary cells or patient-derived models to ensure clinical relevance.
What is the sensitivity level for detecting GFR-driven signals?
Our platforms can detect receptor phosphorylation and dimerization even at very low ligand concentrations (pM range).
How does your service handle "bypass signaling" concerns?
Our multi-tiered approach profiles multiple receptor families simultaneously (ErbB, FGFR, IGF-1R), detecting if a factor inhibits one pathway while inadvertently activating another.
Customer Review
-
Unrivaled Sensitivity in Early Detection
Using Creative Biolabs' service in our research has significantly facilitated the detection of replication stress in our LUAD models. The PCNA phosphorylation data provided a mechanistic link we had missed for months. – Dr. Sarah L***en
-
Comprehensive Metabolic-Mitogenic Mapping
Using Creative Biolabs' profiling service has significantly improved our understanding of IR/IGF-1R hybrid signaling. The ability to distinguish between metabolic and mitogenic flux was critical for our insulin-analog project. – Prof. Michael R***on
Related Services
PBMC mediated ADCC Assay Service
Creative Biolabs provides PBMC-mediated ADCC assays to measure antibody cytotoxic potency. Our high-resolution platforms deliver reliable data on immune-mediated cell killing for therapeutic antibody development.
Learn More →
In Vitro Cell Culture Service
Creative Biolabs provides stringent cell culture services, offering primary, tumor, and iPS cells. We specialize in customized models and therapeutic protein production to support complex downstream assays.
Learn More →
How to Contact Creative Biolabs
Creative Biolabs provides the definitive platform for decoding the mitogenic potential of your leads through a high-resolution growth factor receptor driven proliferation profiling service. From initial receptor engagement to the final cell cycle exit, we offer the expertise and technology to ensure your projects move forward with confidence and clarity.
Contact Our Team for More Information and to Discuss Your Project
Reference
-
Czyz, Malgorzata. "Fibroblast growth factor receptor signaling in skin cancers." Cells 8.6 (2019): 540. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/cells8060540
For Research Use Only | Not For Clinical Use
Download our brochure